DETERMINING REFERENCE RANGES FOR TREC AND KREC ASSAYS IN IMMUNE DEFICIENCY SCREENING OF NEWBORNS IN RUSSIAN FEDERATION
https://doi.org/10.15789/1563-0625-2019-3-527-538
Abstract
In this work, we used a reference population of newborns and sampled dried blood spots on Guthrie cards of 2,739 individual samples to determine the reference intervals for TRECs and KRECs values, in order to diagnose primary immunodeficiency by means of neonatal screening. The median absolute values for TRECs and KRECs were 195 (CI95%: 185-206) and 185 (CI95%: 176-197) copies per μl, respectively; the normalized value for TRECs was 2780 (CI95%: 2690-2840), and for KRECs, 2790 (CI95%: 2700-2900) copies per 2 × 105 copies of the albumin gene or 105 cells. The reference interval was calculated for 99 and 99.9 percentiles of total TRECs and KRECs individual values. Due to asymmetric distribution of data, the outliers were filtered off, using the Tukey’s criterion applied after logarithmic transformation of the data. When analyzing absolute values for TREC/KREC (per μL of blood), no “drop-down” TRECs values were identified; for KRECs, 18 experimental values were excluded from further analysis (from 9.8 to 13.5). The outlying values were not identified among the normalized values of TRECs/KRECs. The obtained reference values for TRECs and KRECs (at the 0.1 percentile level) were, respectively, 458 and 32 per 105 cells, or 23 and 17 per μl of blood samples from neonates.
Keywords
primary immunodeficiency (PID),
T cells,
B cells,
screening,
TREC,
KREC,
newborn,
reference intervals
About the Authors
M. A. Gordukova
G. Speransky Children’s Hospital No. 9, Moscow
Russian Federation
Russian Federation
Clinical Biologist, Clinical Diagnostic Laboratory
123317, Moscow, Shmitovsky lane, 29.
Phone: 7 (499) 256-21-62. Fax: 7 (499) 256-61-27.
I. A. Korsunsky
G. Speransky Children’s Hospital No. 9, Moscow
Russian Federation
Russian Federation
PhD (Medicine), Head, Moscow City Center for Pediatric Immunology and Allergy
Yu. V. Chursinova
M. Vladimirsky Moscow Regional Research and Clinical Institute (MONIKI)
Russian Federation
Russian Federation
Head, Department of Arrangement and Management of Clinical Studies, Assistant Professor, Department of Clinical Laboratory Diagnostics, Faculty of Postgraduate Education
Moscow
M. M. Byakhova
M. Vladimirsky Moscow Regional Research and Clinical Institute (MONIKI)
Russian Federation
Russian Federation
PhD (Medicine), Senior Research Associate, Pathology Department
Moscow
I. P. Oscorbin
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences
Russian Federation
Russian Federation
PhD (Biology), Junior Research Associate, Laboratory of Pharmacogenomics
Novosibirsk
A. P. Prodeus
G. Speransky Children’s Hospital No. 9, Moscow; Immanuel Kant Baltic Federal University
Russian Federation
Russian Federation
PhD, MD (Medicine), Professor, Deputy Medical Director for Infectious Diseases, Moscow;
Consulting Professor, Kaliningrad.
M. L. Filipenko
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences; Novosibirsk State University (NSU)
Russian Federation
Russian Federation
PhD (Biology), Head, Laboratory of Pharmacogenomics Laboratory; Head, Laboratory of Molecular Ddiagnostics
Novosibirsk
References
1. Gordukova M.A., Oscorbin I.P., Mishukova O.V., Zimin S.B., Zinovieva N.V., Davydova N.V., Smirnova A.S., Nikitina I.A., Korsunsky I.A., Filipenko M.L., Prodeus A.P. Development of real-time multiplex PCR for the quantitative determination of TREC’s and KREC’s in whole blood and in dried blood spots. Meditsinskaya immunologiya = Medical Immunology (Russia), 2015, Vol. 17, no. 5, pp. 467-478. (In Russ.) doi:10.15789/1563-0625-2015-5-467-478.
2. GOST R 53022.3 – 2008 National Standard of Russian Federation. Clinical laboratory technologies. Requirements to the quality of clinical laboratory studies. Part 3. Rules for evaluating the clinical informativity of laboratory tests.
3. Deryabina S.S., Tuzankina I.A., Shershnev V.N. Determination of reference values for TREC and KREC in dry blood spots of newborns from different gestation ages in Sverdlovsk Region. Meditsinskaya immunologiya = Medical Immunology (Russia), 2018, Vol. 20, no. 1, pp. 85-98. (In Russ.) doi: 10.15789/1563-0625-2018-1-85-98.
4. The Ministry of Health and Social Development of the Russian Federation Order No. 185 issued 22 March 2006 on “Total screening of newborns for hereditary diseases”.
5. Abdelhaleem M., Adeli K., Bamforth F., Callahan J., Chan A., Cheung Chan P., Delvin E., Dooley K., Fu L., Grey V., Kahr W., Lepage N., Lyon M., Meng Q., Potter M., Verjee Z. An editorial on behalf of the CALIPER investigators. Pediatric reference intervals: critical gap analysis and establishment of a national initiative. Clinical Biochemistry, 2006, Vol. 39, pp. 559-560.
6. Adams S.P., Rashid S., Premachandra T., Harvey K., Ifederu A., Wilson M.C., Gaspar H.B. Screening of neonatal UK dried blood spots using a duplex TREC screening assay. J. Clin. Immunol., 2014, Vol. 34, pp. 323-330.
7. Al-Mousa H., Al-Dakheel G., Jabr A., Elbadaoui F., Abouelhoda M., Baig M., Monies D., Meyer B., Hawwari A., Dasouki M. High incidence of severe combined immunodeficiency disease in saudi arabia detected through combined T cell receptor excision circle and next generation sequencing of newborn dried blood spots. Front. Immunol., 2018, Vol. 9, 782. doi:10.3389/fimmu.2018.00782.
8. Audrain M.A.P., Léger A.J.C., Hémont C.A.F., Mirallié S.M., Cheillan D., Rimbert M.G.M., Le Thuaut A.M., Sébille-Rivain V.A., Prat A., Pinel E.M.Q., Divry E., Dert C.G.L., Fournier M.A.G., Thomas C.J.C. Newborn Screening for severe combined immunodeficiency: Analytic and clinical performance of the T cell receptor excision circle assay in France (DEPISTREC Study). J. Clin. Immunol., 2018, Vol. 38, no. 7, pp. 778-786.
9. Barbaro M., Ohlsson A., Borte S., Jonsson S., Zetterström R.H., King J., Winiarski J., von Döbeln U., Hammarström L. Newborn screening for severe primary immunodeficiency diseases in Sweden – a 2-year pilot TREC and KREC screening study. J. Clin. Immunol., 2017, Vol. 1, pp. 51-60.
10. Blom M., Pico-Knijnenburg I., Sijne-van Veen M., Boelen A., Bredius R.G.M.., van der Burg M., Schielen P.C.J.I. An evaluation of the TREC assay with regard to the integration of SCID screening into the Dutch newborn screening program. Clin. Immunol., 2017, Vol. 180, pp. 106-110.
11. Borte S., Meeths M., Liebscher I., Krist K., Nordenskjöld M., Hammarström L., von Döbeln U., Henter J.I., Bryceson Y.T. Combined newborn screening for familial hemophagocytic lymphohistiocytosis and severe T- and B-cell immunodeficiencies. J. Allergy Clin. Immunol., 2014, Vol. 134, no. 1, pp. 226-228.
12. Borte S., von Dobeln U., Fasth A., Wang N., Janzi M., Winiarski J., Sack U., Pan-Hammarström Q., Borte M., Hammarström L. Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR. Blood, 2012, Vol. 119, pp. 2552-2555.
13. Chien Y.H., Chiang S.C., Chang K.L., Yu H.H., Lee W.I., Tsai L.P., Hsu L.W., Hu M.H., Hwu W.L. Incidence of severe combined immunodeficiency through newborn screening in a Chinese population. J. Formos. Med. Assoc., 2015, Vol. 114, pp. 12-16.
14. Chien Y.H., Yu H.H., Lee N.C., Ho H.C., Kao S.M., Lu M.Y., Jaing T.H., Lee W.I., Chang K.W., Shieh C.C., Chen J.S., Chiang S.C., Liu C.C., Hwu W.L. Newborn screening for severe combined immunodeficiency in Taiwan. Int. J. Neonatal Screen., 2017, Vol. 3, no. 16, 12 p.
15. D’Agostino R.B., Belanger A., d’Agostino R.B. Jr. A suggestion for using powerful and informative tests of normality. Am. Statistician, 1990, Vol. 44, no. 4, pp. 316-321.
16. Dar N., Gothelf D., Korn D., Frisch A., Weizman A., Michaelovsky E., Carmel M., Yeshayahu Y., DubnovRaz G., Pessach I.M., Simon A.J., Lev A., Somech R. Thymic and bone marrow output in individuals with 22q11.2 deletion syndrome. Pediatr Res., 2015, Vol. 77, no. 4, pp. 579-585.
17. de Felipe B., Olbrich P., Lucenas J.M., Delgado-Pecellin C., Pavon-Delgado A., Marquez J., Salamanca C., Soler-Palacin P., Gonzalez-Granado L.I., Antolin L.F., Borte S., Neth O. Prospective neonatal screening for severe T- and B-lymphocyte deficiencies in Seville. Pediatr Allergy Immunol., 2016, Vol. 27, no. 1, pp. 70-77.
18. Dixon W.J. Processing data for outliers. Biometrics, 1953, Vol. 9, no. 1, pp. 74-89.
19. Ezzelle J., Rodriguez-Chavez I.R., Darden J.M., Stirewalt M., Kunwar N., Hitchcock R., Walter T., D’Souza M.P. Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. J. Pharm. Biomed. Anal., 2008, Vol. 46, no. 1, pp. 18-29.
20. Froňková E., Klocperk A., Svatoň M., Nováková M., Kotrová M., Kayserová J., Kalina T., Keslová P., Votava F., Vinohradská H., Freiberger T., Mejstříková E., Trka J., Sedivá A. The TREC/KREC assay for the diagnosis and monitoring of patients with DiGeorge syndrome. PLoS ONE, 2014, Vol. 9, no. 12, e114514. doi: 10.1371/journal.pone.0114514.
21. Grasbeck R., Saris N.E. Establishment and use of normal values. Scand. J. Clin. Lab. Invest., 1969, Vol. 26, pp. 62-63.
22. Gul K.A., Øverland T., Osnes L., Baumbusch L.O., Pettersen R.D., Lima K., Abrahamsen T.G. Neonatal levels of T-cell receptor excision circles (TREC) in patients with 22q11.2 deletion syndrome and later disease features. J. Clin. Immunol., 2015, Vol. 35, pp. 408-415.
23. Horn P.S., Pesce A.J. Reference intervals: an update. Clinica Chimica Acta, 2003, Vol. 334, iss. 1-2, pp. 5-23.
24. Horowitz G.L, Altaie S., Boyd J.C., Ceriotti F., Garg U., Horn P., Pesce A., Harrison E. Sine H.E., Zakowski J. National Committee for Clinical Laboratory Standards EP28-A3c defining, establishing, and verifying reference intervals in the clinical laboratory; Approved guideline. Third Edition. Vol. 28, no. 30.
25. Kamae C., Nakagawa N., Sato H., Honma K., Mitsuiki N., Ohara O. Common variable immunodeficiency classification by quantifying T-cell receptor and immunoglobulin κ-deleting recombination excision circles. J. Allergy Clin. Immunol., 2013, Vol. 131, pp. 1437-1440.e5.
26. Kanegae M.P.P., Barreiros L.A., Sousa J.L., Brito M.A.S., Oliveira E.B. Jr., Soares L.P., Mazzucchelli J.T.L., Fernandes D.Q., Hadachi S.M., Holanda S.M., Guimarães F.A.T.M., Boacnin M.A.P.V.V., Pereira M.A.L., Bueno J.M.C., Grumach A.S., Gesu R.S.W.D., Santos A.M.N.D., Bellesi N., Costa-Carvalho B.T., Condino-Neto A. Screening for severe combined immunodeficiencies using trecs and krecs: second pilot study in brazil. Rev. Paul Pediatr., 2017, Vol. 35, no. 1, pp. 25-32.
27. Kraus M., Lev A., Simon A.J., Levran I., Nissenkorn A., Levi Y.B., Berkun Y., Efrati O., Amariglio N., Rechavi G., Somech R. Disturbed B and T cell homeostasis and neogenesis in patients with ataxia telangiectasia. J. Clin. Immunol., 2014, Vol. 34, no. 5, pp. 561-572.
28. Kwan A., Abraham R.S., Currier R., Brower A., Andruszewski K., Abbott J.K., Baker M., Ballow M., Bartoshesky L.E., Bonilla F.A., Brokopp C., Brooks E., Caggana M., Celestin J., Church J.A., Comeau A.M., Connelly J.A., Cowan M.J., Cunningham-Rundles C., Dasu T., Dave N., de la Morena M.T., Duffner U., Fong C.T., Forbes L., Freedenberg D., Gelfand E.W., Hale J.E., Hanson I.C., Hay B.N., Hu D., Infante A., Johnson D., Kapoor N., Kay D.M., Kohn D.B., Lee R., Lehman H., Lin Z., Lorey F., Abdel-Mageed A., Manning A., McGhee S., Moore T.B., Naides S.J., Notarangelo L.D., Orange J.S., Pai S.Y., Porteus M., Rodriguez R., Romberg N., Routes J., Ruehle M., Rubenstein A., Saavedra-Matiz C.A., Scott G., Scott P.M., Secord E., Seroogy C., Shearer W.T., Siegel S., Silvers S.K., Stiehm E.R., Sugerman R.W., Sullivan J.L., Tanksley S., Tierce M.L. 4 th , Verbsky J., Vogel B., Walker R., Walkovich K., Walter J.E., Wasserman R.L., Watson M.S., Weinberg G.A., Weiner L.B., Wood H., Yates A.B., Puck J.M., Bonagura V.R. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA, 2014, Vol. 312, no. 7, pp.729-738.
29. Kwan A., Church J.A., Cowan M.J., Agarwal R., Kapoor N., Kohn D.B., Lewis D.B., McGhee S.A., Moore T.B., Stiehm E.R., Porteus M., Aznar C.P., Currier R., Lorey F., Puck J.M. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J. Allergy Clin. Immunol., 2013, Vol. 132, pp. 140-150.
30. la Marca G., Canessa C., Giocaliere E., Romano F., Malvagia S., Funghini S., Moriondo M., Valleriani C., Lippi F., Ombrone D., Della Bona ML., Speckmann C., Borte S., Brodszki N., Gennery A.R., Weinacht K., Celmeli F., Pagel J., de Martino M., Guerrini R., Wittkowski H., Santisteban I., Bali P., Ikinciogullari A., Hershfield M., Notarangelo LD., Resti M., Azzari C. Diagnosis of immunodeficiency caused by a purine nucleoside phosphorylase defect by using tandem mass spectrometry on dried blood spots. J. Allergy Clin. Immunol., 2014, Vol. 134, no. 1, pp. 155-159.
31. Liao H.C., Liao C.H., Kao S.M., Chiang C.C., Chen Y.J. Detecting 22q11. 2 deletion syndrome in newborns with low T Cell receptor excision circles from severe combined immunodeficiency screening. J. Pediatr., 2019, Vol. 204, pp. 219-224.e1.
32. Lingman Framme J., Borte S., von Döbeln U., Hammarström L., Oskarsdóttir S. Retrospective analysis of TREC based newborn screening results and clinical phenotypes in infants with the 22q11 deletion syndrome. J. Clin. Immunol., 2014, Vol. 34, no. 4, pp. 514-519.
33. Linnet K. Two-stage transformations for normalization of reference distributions evaluated. Clin. Chem., 1987, Vol. 33, pp. 381-386.
34. Mahlaoui N., Gathmann B., Kindle G., Ehl S., on behalf of the ESID Registry Working Party Steering Committee (Quinti I., Grimbacher B., Buckland M., Seidel M., van Montfrans J., and the ESID Society. The European Society for Immunodeficiencies (ESID) Registry: recent advancements in the epidemiology of Primary Immunodeficiencies and how does that translate in clinical care. Rare Dis. Orph. Drugs, 2014, Vol. 1, no. 4, Suppl. 4.
35. Mahlaoui N., Jais J.P., Brosselin P., Mignot C., Beaurain B., Brito C., Costes L., Courteille V., de Vergnes N., Alcaïs A., Fischer A.; CEREDIH Prevalence Study Collaborators. Prevalence of primary immunodeficiencies in France is underestimated. J. Allergy Clin. Immunol., 2017, Vol. 140, no. 6, pp. 1731-1733.
36. Marschall K., Hoernes M., Bitzenhofer-Grüber M., Jandus P., Duppenthaler A., Wuillemin W.A., Rischewski J., Boyman O., Heininger U., Hauser T., Steiner U., Posfay-Barbe K., Seebach J., Recher M., Hess C., Helbling A., Reichenbach J.; Swiss PID Registry Working Group. The Swiss National Registry for Primary Immunodeficiencies: report on the first 6 years’ activity from 2008 to 2014. Clin. Exp. Immunol., 2015, Vol. 182, no. 1, pp. 45-50.
37. Mayo Foundation for Medical Education and Research, Test ID: CBC. [Electronic resource]. Access mode: https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/9109.
38. National Committee for Clinical Laboratory Standards. NCCLS. How to define and determine reference intervals in the clinical laboratory; Approved guideline. Second Edition. NCCLS document C28-A2, 2000, Vol. 20, no. 13.
39. Nourizadeh M., Shakerian L., Borte S., Fazlollahi M., Badalzadeh M., Houshmand M., Alizadeh Z., Dalili H., Rashidi-Nezhad A., Kazemnejad A., Moin M., Hammarström L., Pourpak Z. Newborn screening using TREC/ KREC assay for severe T and B cell lymphopenia in Iran. Scand. J. Immunol., 2018, Vol. 6, e12699. doi:10.1111/sji.12699.
40. Poole S., Schroeder L.F., Shah N. An unsupervised learning method to identify reference intervals from a clinical database. J. Biomed. Inform., 2016, Vol. 59, pp. 276-284.
41. Puck J.M. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. Immunol. Rev., 2019, Vol. 287, no. 1, pp. 241-252.
42. Rechavi E., Lev A., Simon A.J., Stauber T., Daas S., Saraf-Levy T., Broides A., Nahum A., Marcus N., Hanna S., Stepensky P., Toker O., Dalal I., Etzioni A., Almashanu S., Somech R. First year of Israeli newborn screening for severe combined immunodeficiency – clinical achievements and insights. Front. Immunol., 2017, Vol. 6, no. 8, 1448. doi:10.3389/fimmu.2017.01448.
43. Richards S., Pitt J., Choo S. Newborn screening for severe combined immunodeficiency: Evaluation of a commercial T-cell receptor excision circle-based method in Victorian dried blood spots. J. Paediatr. Child Health., 2018, Vol. 54, no. 1, pp. 14-19.
44. Routes J.M., Grossman W.J., Verbsky J., Laessig R.H., Hoffman G.L., Brokopp C.D., Baker M.W. Statewide newborn screening for severe T-cell lymphopenia. JAMA, 2009, Vol. 302, no. 22, pp. 2465-2470.
45. Shillitoe B., Bangs C., Guzman D., Gennery A.R., Longhurst H.J., Slatter M., Edgar D.M., Thomas M., Worth A., Huissoon A., Arkwright P.D., Jolles S., Bourne H., Alachkar H., Savic S., Kumararatne D.S., Patel S., Baxendale H., Noorani S., Yong P.F.K., Waruiru C., Pavaladurai V., Kelleher P., Herriot R., Bernatonienne J., Bhole M., Steele C., Hayman G., Richter A., Gompels M., Chopra C., Garcez T., Buckland M. The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017. Clin. Exp. Immunol., 2018, Vol. 192, no. 3, pp. 284-291.
46. Solberg H.E.. The IFCC recommendation on estimation of reference intervals. The RefVal program. Clin. Chem. Lab. Med., 2004, Vol. 42, no. 7, pp. 710-714.
47. Somech R., Lev A., Simon A.J., Korn D., Garty B.Z., Amariglio N., Rechavi G., Almashanu S., Zlotogora J., Etzioni A. Newborn screening for severe T and B cell immunodeficiency in Israel: a pilot study. Isr. Med. Assoc. J., 2013, Vol. 15, pp. 404-409.
48. Speckmann C., Neumann C., Borte S., la Marca G., Sass J.O., Wiech E., Fisch P., Schwarz K., Buchholz B., Schlesier M., Felgentreff K., Grimbacher B., Santisteban I., Bali P., Hershfield M.S., Ehl S. Delayed-onset adenosine deaminase deficiency: strategies for an early diagnosis.J. Allergy Clin. Immunol., 2012, Vol. 130, no. 4, pp. 991-994.
49. Tagliaferri L., Kunz J.B., Happich M., Esposito S., Bruckner T., Hübschmann D., Okun J.G., Hoffmann G.F., Schulz A., Kappe J., Speckmann C., Muckenthaler M.U., Kulozik A.E. Newborn screening for severe combined immunodeficiency using a novel and simplified method to measure T-cell excision circles (TREC). Clin. Immunol., 2017, Vol. 175, pp. 51-55.
50. Tamura S., Higuchi K., Tamaki M., Inoue C., Awazawa R., Mitsuki N., Nakazawa Y., Mishima H., Takahashi K., Kondo O., Imai K., Morio T., Ohara O., Ogi T., Furukawa F., Inoue M., Yoshiura K., Kanazawa N. Novel compound heterozygous DNA ligase IV mutations in an adolescent with a slowly-progressing radiosensitivesevere combined immunodeficiency. Clin. Immunol., 2015, Vol. 160, no. 2, pp. 255-260.
51. Taneja A., Chhabra A. Bruton Agammaglobulinemia. StatPearls [Internet], 2018. [Electronic resource]. Access mode: https://www.ncbi.nlm.nih.gov/books/NBK448170/.
52. Tukey J.W. Exploratory Data Analysis. Addison Wesley, 1977.
53. Verbsky J.W., Baker M.W., Grossman W.J., Hintermeyer M., Dasu T., Bonacci B., Reddy S., Margolis D., Casper J., Gries M., Desantes K., Hoffman G.L., Brokopp C.D., Seroogy C.M., Routes J.M. Newborn screening for severe combined immunodeficiency; the Wisconsin experience (2008-2011). J. Clin. Immunol., 2012, Vol. 32, pp. 82-88.
54. Verstegen R.H., Borte S., Bok L.A., van Zwieten P.H., von Döbeln U., Hammarström L., de Vries E. Impact of Down syndrome on the performance of neonatal screening assays for severe primary immunodeficiency diseases. J. Allergy Clin. Immunol., 2014, Vol. 133, no. 4, pp. 1208-1211.
Review
For citations:
Gordukova M.A., Korsunsky I.A., Chursinova Yu.V., Byakhova M.M., Oscorbin I.P., Prodeus A.P., Filipenko M.L. DETERMINING REFERENCE RANGES FOR TREC AND KREC ASSAYS IN IMMUNE DEFICIENCY SCREENING OF NEWBORNS IN RUSSIAN FEDERATION. Medical Immunology (Russia). 2019;21(3):527-538. (In Russ.) https://doi.org/10.15789/1563-0625-2019-3-527-538
Views:
5409
Email this article 